Links to protocol summaries of current & upcoming clinical trials at the Case site
February 2020
5359: Latitude, a phase III, randomized, cross-over study to evaluate long-acting injectable antiretroviral therapy for people living with HIV who have not been adherent to their antiretroviral therapy in pill form. Latitude A5359 Provider Summary
5377: TRIO, a phase I, First-in-Human, Ascending Dose Study of SAR441236, a Tri-Specific Broadly Neutralizing Antibody, in Participants with HIV. Currently looking for ART-naive participants for Arm B of trial. TRIO A5377 provider summary v2